Clinical trial NCT00264420 - References

Breast Cancer — Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation

Citation(s)

•   ABRAMS HL, SPIRO R, GOLDSTEIN N
  Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer. 1950 Jan;3(1):74-85.
•   Adami S, Salvagno G, Guarrera G, Bianchi G, Dorizzi R, Rosini S, Mobilio G, Lo Cascio V
  Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985 Dec;134(6):1152-4.
•   Algur E, Macklis RM, Häfeli UO
  Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):535-42.
•   Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A
  In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998 Feb;12(2):220-9.
•   Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD
  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996 Feb 22;334(8):488-93.
•   Berenson JR, Vescio R, Henick K, Nishikubo C, Rettig M, Swift RA, Conde F, Von Teichert JM
  A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer. 2001 Jan 1;91(1):144-54.
•   Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Tutor C, Amesur N, Avril N
  90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):778-87. Epub 2005 Mar 17.
•   Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J
  Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res. 1998 Nov;13(11):1775-82.
•   Blitzer PH
  Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer. 1985 Apr 1;55(7):1468-72.
•   Body JJ, Borkowski A, Cleeren A, Bijvoet OL
  Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol. 1986 Aug;4(8):1177-83.
•   Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J
  A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res. 1999 Sep;14(9):1557-61.
•   Body JJ, Magritte A, Seraj F, Sculier JP, Borkowski A
  Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions. J Bone Miner Res. 1989 Dec;4(6):923-8.
•   Body JJ
  Clinical research update: zoledronate. Cancer. 1997 Oct 15;80(8 Suppl):1699-701. Review.
•   Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P
  Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000 Jun 1;60(11):2949-54.
•   Boonekamp PM, Löwik CW, van der Wee-Pals LJ, van Wijk-van Lennep ML, Bijvoet OL
  Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner. 1987 Feb;2(1):29-42.
•   Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL
  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986 Feb;1(1):27-39.
•   Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F
  Renal failure associated with intravenous diphosphonates. Lancet. 1983 Feb 26;1(8322):471.
•   Brown JE, Neville-Webbe H, Coleman RE
  The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer. 2004 Jun;11(2):207-24. Review.
•   Cantwell BM, Harris AL
  Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br Med J (Clin Res Ed). 1987 Feb 21;294(6570):467-9.
•   Chow E, Danjoux C, Wong R, Szumacher E, Franssen E, Fung K, Finkelstein J, Andersson L, Connolly R
  Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol. 2000 Sep;56(3):305-14.
•   Clarke NW, McClure J, George NJ
  Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 1992 Jan;69(1):64-70.
•   Clarke NW, McClure J, George NJ
  Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991 Jul;68(1):74-80.
•   Coleman RE, Houston S, James I, Rodger A, Rubens RD, Leonard RC, Ford J
  Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer. 1992 May;65(5):766-8.
•   Coleman RE, Rubens RD
  3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br J Cancer. 1987 Oct;56(4):465-9.
•   Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD
  Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer. 1988 Nov;58(5):621-5.
•   Coleman RE
  Bisphosphonates: clinical experience. Oncologist. 2004;9 Suppl 4:14-27. Review.
•   Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, Bonneterre J, Francini G, Ford JM
  Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996 Sep;14(9):2552-9.
•   Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Guglielmo R
  Production of interleukin-1 by bone marrow myeloma cells. Blood. 1989 Jul;74(1):380-7.
•   Elomaa I, Blomqvist C, Gröhn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmström T
  Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet. 1983 Jan 22;1(8317):146-9.
•   Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, Lievshitz G, Ron I, Mishani E
  Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004 Feb;45(2):272-8.
•   Falkmer U, Järhult J, Wersäll P, Cavallin-Ståhl E
  A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol. 2003;42(5-6):620-33. Review.
•   Flanagan AM, Chambers TJ
  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int. 1991 Dec;49(6):407-15.
•   Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR
  Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):607-11. Epub 2003 Feb 13.
•   Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C
  The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain. 1998 Dec;78(3):157-69. Review.
•   Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD
  Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000 Feb;82(4):858-64.
•   Garrett IR, Durie BG, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR
  Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med. 1987 Aug 27;317(9):526-32.
•   Green JR, Müller K, Jaeggi KA
  Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994 May;9(5):745-51.
•   Green JR, Seltenmeyer Y, Jaeggi KA, Widler L
  Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol. 1997 May;80(5):225-30.
•   Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R, et al
  Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol. 1992 Jan;10(1):134-42.
•   Guise TA
  Molecular mechanisms of osteolytic bone metastases. Cancer. 2000 Jun 15;88(12 Suppl):2892-8. Review.
•   Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL
  Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed). 1987 Nov 21;295(6609):1301-5.
•   Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, Yoneda T
  Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer. 2003 Oct 10;106(6):973-9.
•   Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD
  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996 Dec 12;335(24):1785-91.
•   Hoskin PJ, Price P, Easton D, Regan J, Austin D, Palmer S, Yarnold JR
  A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother Oncol. 1992 Feb;23(2):74-8.
•   Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR
  Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000 Apr 22;355(9213):1428-9.
•   Hughes DE, MacDonald BR, Russell RG, Gowen M
  Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989 Jun;83(6):1930-5.
•   Ikeda I, Miura T, Kondo I
  Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol. 1996 Jan;77(1):102-6.
•   Ishimori T, Saga T, Nagata Y, Nakamoto Y, Higashi T, Mamede M, Mukai T, Negoro Y, Aoki T, Hiraoka M, Konishi J
  18F-FDG and 11C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med. 2004 Dec;18(8):669-74.
•   Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI
  The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001 Apr 20;84(8):1126-34.
•   Jung A, Bornand J, Mermillod B, Edouard C, Meunier PJ
  Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer Res. 1984 Jul;44(7):3007-11.
•   Kagan AR, Rose CM, Bedwinek JM, Blitzer PH, Brascho DJ, Brown AP, Coia LR, Earle JD, Janjan NA, Lowy RO, Pieters RS Jr, Rotman M, Leibel SA
  Bone metastases. American College of Radiology. ACR Appropriateness Criteria. Radiology. 2000 Jun;215 Suppl:1077-104.
•   Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG
  Effects of intravenous diphosphonates on renal function. Lancet. 1983 Jun 11;1(8337):1328.
•   Kellihan MJ, Mangino PD
  Pamidronate. Ann Pharmacother. 1992 Oct;26(10):1262-9. Review.
•   Keyes JW Jr
  SUV: standard uptake or silly useless value? J Nucl Med. 1995 Oct;36(10):1836-9.
•   Koswig S, Budach V
  [Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study]. Strahlenther Onkol. 1999 Oct;175(10):500-8. German.
•   Kouloulias V, Matsopoulos G, Kouvaris J, Dardoufas C, Bottomley A, Varela M, Uzunoglu N, Antypas C, Metafa A, Moulopoulos A, Sandilos P, Vlahos L
  Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs. Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):143-57.
•   Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I
  Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992 Oct 31;340(8827):1049-52. Erratum in: Lancet 1992 Dec 5;340(8832):1420.
•   Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC
  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003 Jun 19;348(25):2500-7.
•   Lee MV, Fong EM, Singer FR, Guenette RS
  Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001 Mar 15;61(6):2602-8.
•   Lipton A, Berenson JR
  Bisphosphonate treatment of lytic bone metastases. Drugs Aging. 1999 Apr;14(4):241-6. Review.
•   Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J
  The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002;20 Suppl 2:45-54. Review.
•   Mackie PS, Fisher JL, Zhou H, Choong PF
  Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer. 2001 Apr 6;84(7):951-8.
•   Magnetto S, Boissier S, Delmas PD, Clezardin P
  Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer. 1999 Oct 8;83(2):263-9.
•   Major RJ, Chen BL, et al
  Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone. Proc Am Soc Clin Oncol 22:762, 2003
•   Man Z, Otero AB, Rendo P, Barazzutti L, Sanchez Avalos JC
  Use of pamidronate for multiple myeloma osteolytic lesions. Lancet. 1990 Mar 17;335(8690):663.
•   Martin TJ
  Humoral hypercalcemia of malignancy. Bone Miner. 1988 Apr;4(1):83-9. Review.
•   Masud T, Slevin ML
  Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma. Lancet. 1989 May 6;1(8645):1021-2.
•   Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, Howell A
  Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. BMJ. 1988 Sep 24;297(6651):772-3.
•   Mundy GR, Ibbotson KJ, D'Souza SM, Simpson EL, Jacobs JW, Martin TJ
  The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med. 1984 Jun 28;310(26):1718-27. Review.
•   Mundy GR, Ibbotson KJ, D'Souza SM
  Tumor products and the hypercalcemia of malignancy. J Clin Invest. 1985 Aug;76(2):391-4.
•   Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE
  Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974 Nov 14;291(20):1041-6.
•   Mundy GR, Wilkinson R, Heath DA
  Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med. 1983 Mar;74(3):421-32.
•   Nemoto R, Sato S, Nishijima Y, Miyakawa I, Koiso K, Harada M
  Effects of a new bisphosphonate (AHBuBP) on osteolysis induced by human prostate cancer cells in nude mice. J Urol. 1990 Sep;144(3):770-4.
•   Nemoto R, Satou S, Miyagawa I, Koiso K
  Inhibition by a new bisphosphonate (AHBuBP) of bone resorption induced by the MBT-2 tumor of mice. Cancer. 1991 Feb 1;67(3):643-8.
•   Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, Henderson IC, Mallette LE
  Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993 Sep;95(3):297-304.
•   O'Grady RL, Cameron DA
  Osteoclasts and the resorption of bone by transplanted mammary carcinoma in rats. Br J Cancer. 1985 Jun;51(6):767-74.
•   Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S
  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993 Jan;11(1):59-65.
•   Pelger RC, Lycklama à Nijeholt AA, Papapoulos SE
  Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases. Lancet. 1989 Oct 7;2(8667):865.
•   Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA
  Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 1987 Feb;13(1):41-9.
•   Peterson JJ, Kransdorf MJ, O'Connor MI
  Diagnosis of occult bone metastases: positron emission tomography. Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S120-8. Review.
•   Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR
  Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986 Aug;6(4):247-55.
•   Radl J, Croese JW, Zurcher C, van den Enden-Vieveen MH, Brondijk RJ, Kazil M, Haaijman JJ, Reitsma PH, Bijvoet OL
  Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer. 1985 Mar 1;55(5):1030-40.
•   Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT
  Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989 Nov 18;2(8673):1180-2.
•   Rasmusson B, Vejborg I, Jensen AB, Andersson M, Banning AM, Hoffmann T, Pfeiffer P, Nielsen HK, Sjøgren P
  Irradiation of bone metastases in breast cancer patients: a randomized study with 1 year follow-up. Radiother Oncol. 1995 Mar;34(3):179-84.
•   Reitsma PH, Teitelbaum SL, Bijvoet OL, Kahn AJ
  Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest. 1982 Nov;70(5):927-33.
•   Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC
  The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer. 2002 Jul 29;87(3):366-71.
•   Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Mönkkönen J, Auriola S, Chilton KM, Russell RG
  Molecular mechanisms of action of bisphosphonates. Bone. 1999 May;24(5 Suppl):73S-79S. Review.
•   Rose CM, Kagan AR
  The final report of the expert panel for the radiation oncology bone metastasis work group of the American College of Radiology. Int J Radiat Oncol Biol Phys. 1998 Mar 15;40(5):1117-24. Review.
•   Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y
  Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001 Sep-Oct;7(5):377-87.
•   Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ
  Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 Oct 15;98(8):1735-44.
•   Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J
  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004 Jun 15;100(12):2613-21.
•   Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman JJ
  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 Aug 15;21(16):3150-7.
•   Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE
  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004 Jan 1;100(1):36-43.
•   Russell RG, Rogers MJ
  Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999 Jul;25(1):97-106. Review.
•   Saad F, Chi K, Fleshner N
  The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol. 2004 Oct;11(5):2376-82. Review.
•   Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group
  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68.
•   Sawyer N, Newstead C, Drummond A, Cunningham J
  Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone Miner. 1990 May;9(2):121-8.
•   Schenk R, Eggli P, Fleisch H, Rosini S
  Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986 Jun;38(6):342-9.
•   Scher HI, Chung LW
  Bone metastases: improving the therapeutic index. Semin Oncol. 1994 Oct;21(5):630-56. Review.
•   Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, Messer P, Nüssle K, Elsner K, Glatting G, Träger H, Neumaier B, Diederichs C, Reske SN
  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999 Aug;17(8):2381-9.
•   Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW
  Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000 Apr;82(8):1459-68.
•   Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P
  Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 1983;35(1):87-99.
•   Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI
  Anti-tumour activity of bisphosphonates in human myeloma cells. Leuk Lymphoma. 1998 Dec;32(1-2):129-38. Review.
•   Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F
  The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs. 2001 Jun;12(5):459-65.
•   Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, de Haes H, Martijn H, Oei B, Vonk E, van der Steen-Banasik E, Wiggenraad RG, Hoogenhout J, Wárlám-Rodenhuis C, van Tienhoven G, Wanders R, Pomp J, van Reijn M, van Mierlo I, Rutten E
  The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999 Aug;52(2):101-9. Erratum in: Radiother Oncol 1999 Nov;53(2):167. Leer, J [corrected to Leer, JW]; van Mierlo ,T [corrected to van Mierlo, I].
•   Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE
  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med. 1980 Dec 11;303(24):1377-83.
•   Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M
  Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol. 1996 Nov;156(5):1691-5.
•   Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P, Venuta S
  Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia. 2000 May;14(5):841-4.
•   Taube T, Elomaa I, Blomqvist C, Beneton MN, Kanis JA
  Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone. 1994 Mar-Apr;15(2):161-6.
•   Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, Teronen A, Maisi P, Sorsa T
  MMP inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci. 1999 Jun 30;878:453-65.
•   Thiébaud D, Jaeger P, Jacquet AF, Burckhardt P
  Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol. 1988 May;6(5):762-8.
•   Thiébaud D, Leyvraz S, von Fliedner V, Perey L, Cornu P, Thiébaud S, Burckhardt P
  Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer. 1991;27(1):37-41.
•   Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT
  Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999 Oct;140(10):4451-8.
•   Tong D, Gillick L, Hendrickson FR
  The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982 Sep 1;50(5):893-9.
•   Vakaet LA, Boterberg T
  Pain control by ionizing radiation of bone metastasis. Int J Dev Biol. 2004;48(5-6):599-606. Review.
•   Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME
  Quantitative histology of myeloma-induced bone changes. Br J Haematol. 1982 Dec;52(4):601-10.
•   van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, et al
  Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993 Mar;11(3):491-8.
•   Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE
  Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer. 1996 May;73(9):1089-95.
•   Witters LM, Crispino J, Fraterrigo T, Green J, Lipton A
  Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol. 2003 Aug;26(4):S92-7.
•   Zasadny KR, Wahl RL
  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993 Dec;189(3):847-50.

A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer

Details for clinical trial NCT00264420